News

 

Entrectinib, the kinase inhibitor drug initially discovered and developed by Nerviano Medical Sciences approved by AIFA in two oncology indications

Nerviano, 14 September 2021
Entrectinib, the kinase inhibitor drug that was initially discovered and developed by Nerviano Medical Sciences (a member of NMS Group) and that is now marketed by Roche and partners, has received approval for marketing and reimbursement from the Italian drug agency AIFA in two oncology indications: lung cancer ROS1 kinase fusion positive, and any solid tumor type with NTRK kinase gene fusions.
(Click the title for the complete article)

NMS Group wins China Awards for creating concrete values

Nerviano, 9 February 2021 NMS Group has been named the winner of the “Value creators' category at the prestigious 'China Awards 2021' during the online event held by the Italy China Foundation on Monday 8 February 2021. The “Value creators' award is a...

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO